Inmune Bio Inc.

The sponsor’s clinical interests include the role of inflammation in central nervous system disorders, particularly where inflammatory signaling may contribute to progression of cognitive symptoms. This places emphasis on mechanisms linked to immune activity within the brain.

• Neuroinflammatory pathways
• Immune-mediated brain dysfunction
• Inflammation-associated biomarkers

The research landscape suggests a therapeutic interest in modifying inflammatory processes that intersect with Alzheimer’s pathology.

Trial activity is directed toward cognitive performance in individuals with early-stage disease, highlighting interest in domains such as memory, executive function, and general cognitive decline. The clinical focus remains on measurable changes in cognition relevant to daily function.

• Cognitive performance
• Memory decline
• Executive dysfunction

This area connects neuroscience research with clinical outcomes that are central to early intervention in Alzheimer’s disease.

The sponsor’s research landscape includes biomarker-informed patient selection in neuroscience, linking clinical observation with inflammatory biology. This supports investigation of patient subgroups defined by biological features rather than symptoms alone.

• Biomarker-based stratification
• Neurology
• Inflammation-linked disease activity

Clinical interest in this domain is concentrated on aligning biological markers with therapeutic evaluation in early neurodegenerative disease.